Morphological Control of Crystalline Savolitinib via the Volatile Deep Eutectic Solvent Technique.

Jasmine E Symons, Charlie Hall, James F McCabe, Simon R Hall

Abstract read

In one paragraph

Article in Crystal growth & design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jasmine E SymonsComplex Functional Materials Group, School of Chemistry, University of Bristol, Bristol BS8 1TS, U.K.

Charlie HallComplex Functional Materials Group, School of Chemistry, University of Bristol, Bristol BS8 1TS, United Kingdom; Centre for Doctoral Training in Condensed Matter Physics, HH Wills Physics Laboratory, Bristol BS8 1TL, U.K.

James F McCabeEarly Product Development and Manufacturing, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.ORCID https://orcid.org/0000-0002-6062-2253

Simon R HallComplex Functional Materials Group, School of Chemistry, University of Bristol, Bristol BS8 1TS, U.K.ORCID https://orcid.org/0000-0002-2816-0191

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Savolitinib is a compound that can crystallize in an undesirable, high aspect ratio needle morphology. This morphology type may cause issues in downstream processing. This paper demonstrates a unique method to alter the crystal morphology of savolitinib to make it more processable, resulting in the active pharmaceutical ingredient (API) crystallizing out in considerably more processable stellates. The volatile deep eutectic solvent technique presents a simple and scalable method for changing the crystal morphology while maintaining the polymorph of the API in this case, confirmed via powder X-ray diffraction and differential scanning calorimetry analysis.

Identifiers

PMID38525101

DOI10.1021/acs.cgd.4c00035

PMCPMC10958444

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.